2022 Academy group

Applications Open for the 2022-2023 IASLC Academy

The IASLC Academy is a professional development program for early-career physicians from around the world who are interested in pursuing an academic career in thoracic oncology. Deadline to apply: October 3, 2022.
Landmarks of Nara Japan, including Todaiji Temple

ACLC 2022 Registration Now Open!

The IASLC 2022 Asia Conference on Lung Cancer will take place October 27 – 29, 2022 in Nara, Japan. ACLC will highlight clinical research & management and multidisciplinary care from international leaders across the lung cancer field. Register Today!
LALCA Background - Uraguay

Submit Your Abstract for LALCA 2023

You are invited to submit scientific abstracts for LALCA 2023. Research submitted will be considered for presentation in the largest LATAM gathering in the field of lung and thoracic oncology. Deadline to submit: October 14, 2022.
Applications Open for the 2022-2023 IASLC Academy
ACLC 2022 Registration Now Open!
Submit Your Abstract for LALCA 2023

Homepage

The International Association for the Study of Lung Cancer

The IASLC is a global multidisciplinary organization dedicated to eradication of all forms of lung cancer. From provision of educational events around the world and virtually to research projects and publications that advance the science of lung cancer, the IASLC's members—consisting of medical, surgical, and radiation oncologists, as well as other thoracic oncology specialists such as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient research advocates, patients, and their caregivers—are raising the bar for care of patients with lung cancer.

Explore More

In Focus

LALCA Meeting Graphic

2023 Latin America Conference on Lung Cancer | Call for Abstracts

Lung Cancer is the leading cause of death, not only in Latin America, but worldwide. Building on the success of previous LALCA events, the Scientific Program Committee for the IASLC 2023 Latin America Conference on Lung Cancer is inviting the submission of scientific abstracts. 

Abstracts accepted from August 24, 2022, to October 14, 2022. 

THE IASLC ATLAS OF DIAGNOSTIC IMMUNOHISTOCHEMISTRY (IHC)

New Translations of the IASLC IHC Atlas are available! From IHC biochemistry basics to identifying biomarkers, this text provides a comprehensive view of diagnostic IHC in a reader-friendly format.

Language Guide page 1

IASLC Language Guide

In line with the IASLC Equity Statement and in step with the ASCO Language of Respect, we are proud to announce the release of the IASLC Language Guide. The guide was established to instill best practices with commonly used phrases related to patient care. The IASLC will be folding the language found in the guide into all aspects of thoracic oncology education, from abstracts to faculty guidelines to podium presentations. 

Our Impact

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

Our Impact

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

See More

Our Work

The IASLC Staging Project

The IASLC Staging Project is a global effort to study and improve the current staging system for lung cancer, mesothelioma, thymic and esophageal cancer.

Lung Ambition Alliance

The IASLC has formed an alliance with three other founding organizations to allow scientists, specialists, advocates, and patients to break the barriers limiting progress and double 5-year survival rates of lung cancer by 2025.

In Numbers

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.
45
Years Experience
15K
Number of Research Awards Funded
20.121
JTO Impact Factor
8K+
Members

Upcoming Meetings & Webinars

Endorsed Event
Oct 29 - Oct 29 2022
October 29, 2022 7 am - 5 pm EST
CME Accredited
JTO-CRR_Hero-0820 - Cropped.jpg

Journal of Thoracic Oncology & JTO Clinical and Research Reports

Lung and thoracic specialists count on the IASLC’s journals to provide perspective on innovation in prevention, detention, diagnosis and cutting-edge treatments. As a leading medical journal, JTO focuses on lung and thoracic cancers and is dedicated to presenting original research reviews and opinions from a wide range of disciplines within the medical community. JTO CRR, the official open access journal of the IASLC, complements the JTO by offering authors a gold open access publication option.